The effect of sarpogrelate compared to aspirin in high- or very-high-risk diabetes for primary prevention

Abstract The benefit of aspirin in primary prevention for atherosclerotic cardiovascular diseases (ASCVD) is questionable due to bleeding complications. We analyzed the Korean National Health Insurance data to compare the efficacy and overall bleeding of sarpogrelate, an antiplatelet agent with lowe...

Full description

Saved in:
Bibliographic Details
Main Authors: Soo Hyun Kang, Kilyoon Pack, Jung Ho Kim, Youngwoo Jang
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-87868-x
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832571668313145344
author Soo Hyun Kang
Kilyoon Pack
Jung Ho Kim
Youngwoo Jang
author_facet Soo Hyun Kang
Kilyoon Pack
Jung Ho Kim
Youngwoo Jang
author_sort Soo Hyun Kang
collection DOAJ
description Abstract The benefit of aspirin in primary prevention for atherosclerotic cardiovascular diseases (ASCVD) is questionable due to bleeding complications. We analyzed the Korean National Health Insurance data to compare the efficacy and overall bleeding of sarpogrelate, an antiplatelet agent with lower bleeding risk, versus aspirin in high-/very-high-risk diabetic populations without prior ASCVD. The primary endpoint was net adverse clinical events (NACE), defined as a composite of efficacy and overall bleeding. The efficacy was a composite of all-cause death, myocardial infarction (MI) and stroke, whereas overall bleeding included intracranial hemorrhage (ICH) and gastrointestinal (GI) bleeding. A total of 10,778 high-/very-high-risk diabetic patients (9550 on aspirin, 1228 on sarpogrelate) were analyzed. After propensity score matching, sarpogrelate was linked to a lower incidence of NACE (HR:0.71; 95% CI 0.57–0.88), mainly driven by 62% reductions in overall bleeding (0.38; 0.17–0.81), a composite of 64% and 72% lower rate of GI bleeding and ICH, respectively. Additionally, there was no significant differences in MI or stroke between groups. In high- or very-high-risk diabetic patients without ASCVD, sarpogrelate use was associated with net clinical benefit mainly due to the reduction of significant reduction in overall bleeding events.
format Article
id doaj-art-8b30448363f14b30a092095dae29cd2f
institution Kabale University
issn 2045-2322
language English
publishDate 2025-01-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-8b30448363f14b30a092095dae29cd2f2025-02-02T12:24:15ZengNature PortfolioScientific Reports2045-23222025-01-0115111210.1038/s41598-025-87868-xThe effect of sarpogrelate compared to aspirin in high- or very-high-risk diabetes for primary preventionSoo Hyun Kang0Kilyoon Pack1Jung Ho Kim2Youngwoo Jang3Gachon Medical Research Institute, Gachon Biomedical Convergence Institute, Gachon University Gil Medical Center, College of Medicine, Gachon UniversityDivision of Cardiology, Gachon University Gil Medical Center, Gachon University College of MedicineGachon Medical Research Institute, Gachon Biomedical Convergence Institute, Gachon University Gil Medical Center, College of Medicine, Gachon UniversityGachon Medical Research Institute, Gachon Biomedical Convergence Institute, Gachon University Gil Medical Center, College of Medicine, Gachon UniversityAbstract The benefit of aspirin in primary prevention for atherosclerotic cardiovascular diseases (ASCVD) is questionable due to bleeding complications. We analyzed the Korean National Health Insurance data to compare the efficacy and overall bleeding of sarpogrelate, an antiplatelet agent with lower bleeding risk, versus aspirin in high-/very-high-risk diabetic populations without prior ASCVD. The primary endpoint was net adverse clinical events (NACE), defined as a composite of efficacy and overall bleeding. The efficacy was a composite of all-cause death, myocardial infarction (MI) and stroke, whereas overall bleeding included intracranial hemorrhage (ICH) and gastrointestinal (GI) bleeding. A total of 10,778 high-/very-high-risk diabetic patients (9550 on aspirin, 1228 on sarpogrelate) were analyzed. After propensity score matching, sarpogrelate was linked to a lower incidence of NACE (HR:0.71; 95% CI 0.57–0.88), mainly driven by 62% reductions in overall bleeding (0.38; 0.17–0.81), a composite of 64% and 72% lower rate of GI bleeding and ICH, respectively. Additionally, there was no significant differences in MI or stroke between groups. In high- or very-high-risk diabetic patients without ASCVD, sarpogrelate use was associated with net clinical benefit mainly due to the reduction of significant reduction in overall bleeding events.https://doi.org/10.1038/s41598-025-87868-xAspirinDiabetesBleedingPrimary preventionSarpogrelate, antiplatelet therapy
spellingShingle Soo Hyun Kang
Kilyoon Pack
Jung Ho Kim
Youngwoo Jang
The effect of sarpogrelate compared to aspirin in high- or very-high-risk diabetes for primary prevention
Scientific Reports
Aspirin
Diabetes
Bleeding
Primary prevention
Sarpogrelate, antiplatelet therapy
title The effect of sarpogrelate compared to aspirin in high- or very-high-risk diabetes for primary prevention
title_full The effect of sarpogrelate compared to aspirin in high- or very-high-risk diabetes for primary prevention
title_fullStr The effect of sarpogrelate compared to aspirin in high- or very-high-risk diabetes for primary prevention
title_full_unstemmed The effect of sarpogrelate compared to aspirin in high- or very-high-risk diabetes for primary prevention
title_short The effect of sarpogrelate compared to aspirin in high- or very-high-risk diabetes for primary prevention
title_sort effect of sarpogrelate compared to aspirin in high or very high risk diabetes for primary prevention
topic Aspirin
Diabetes
Bleeding
Primary prevention
Sarpogrelate, antiplatelet therapy
url https://doi.org/10.1038/s41598-025-87868-x
work_keys_str_mv AT soohyunkang theeffectofsarpogrelatecomparedtoaspirininhighorveryhighriskdiabetesforprimaryprevention
AT kilyoonpack theeffectofsarpogrelatecomparedtoaspirininhighorveryhighriskdiabetesforprimaryprevention
AT junghokim theeffectofsarpogrelatecomparedtoaspirininhighorveryhighriskdiabetesforprimaryprevention
AT youngwoojang theeffectofsarpogrelatecomparedtoaspirininhighorveryhighriskdiabetesforprimaryprevention
AT soohyunkang effectofsarpogrelatecomparedtoaspirininhighorveryhighriskdiabetesforprimaryprevention
AT kilyoonpack effectofsarpogrelatecomparedtoaspirininhighorveryhighriskdiabetesforprimaryprevention
AT junghokim effectofsarpogrelatecomparedtoaspirininhighorveryhighriskdiabetesforprimaryprevention
AT youngwoojang effectofsarpogrelatecomparedtoaspirininhighorveryhighriskdiabetesforprimaryprevention